{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.0","upperLimit":"5.6","value":"3.13"},{"groupId":"OG001","lowerLimit":"2.1","upperLimit":"10.7","value":"5.27"},{"groupId":"OG002","lowerLimit":"1.1","upperLimit":"4.5","value":"1.53"},{"groupId":"OG003","lowerLimit":"0.6","upperLimit":"8.6","value":"1.32"},{"groupId":"OG004","lowerLimit":"1.2","upperLimit":"13.5","value":"5.88"},{"groupId":"OG005","lowerLimit":"1.7","upperLimit":"17.2","value":"7.22"},{"groupId":"OG006","lowerLimit":"3.5","upperLimit":"38.9","value":"9.59"},{"groupId":"OG007","lowerLimit":"1.4","upperLimit":"17.4","value":"6.82"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"14"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"15"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1"},{"categories":[{"measurements":[{"groupId":"OG004","lowerLimit":"2.7","upperLimit":"33.2","value":"12.30"},{"groupId":"OG006","lowerLimit":"7.8","upperLimit":"22.6","value":"12.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"CYCLE 1 DAY 8"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"0.6","upperLimit":"18.8","value":"7.97"},{"groupId":"OG004","lowerLimit":"1.2","upperLimit":"27.7","value":"14.95"},{"groupId":"OG005","lowerLimit":"0.6","upperLimit":"22.8","value":"3.62"},{"groupId":"OG006","lowerLimit":"5.3","upperLimit":"25.1","value":"11.20"},{"groupId":"OG007","lowerLimit":"1.9","upperLimit":"13.2","value":"5.27"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"8"}],"units":"Participants"}],"title":"WEEK 4 DAY 1"},{"categories":[{"measurements":[{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG000","lowerLimit":"2.7","upperLimit":"5.7","value":"NA"},{"groupId":"OG001","lowerLimit":"2.6","upperLimit":"22.2","value":"7.66"},{"groupId":"OG002","lowerLimit":"1.4","upperLimit":"6.5","value":"1.72"},{"groupId":"OG003","lowerLimit":"1.9","upperLimit":"5.8","value":"2.32"},{"groupId":"OG004","lowerLimit":"10.3","upperLimit":"34.0","value":"19.40"},{"groupId":"OG005","lowerLimit":"1.1","upperLimit":"21.7","value":"1.35"},{"groupId":"OG006","lowerLimit":"19.1","upperLimit":"31.0","value":"26.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"WEEK 7 DAY 1"},{"categories":[{"measurements":[{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG004","lowerLimit":"1.5","upperLimit":"1.5","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"WEEK 7 DAY 8"},{"categories":[{"measurements":[{"groupId":"OG002","lowerLimit":"1.4","upperLimit":"3.4","value":"3.07"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG003","lowerLimit":"2.3","upperLimit":"2.3","value":"NA"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG004","lowerLimit":"16.6","upperLimit":"16.6","value":"NA"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG006","lowerLimit":"20.7","upperLimit":"20.7","value":"NA"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG007","lowerLimit":"23.0","upperLimit":"23.0","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"}],"units":"Participants"}],"title":"WEEK 10 DAY 1"},{"categories":[{"measurements":[{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG000","lowerLimit":"12.0","upperLimit":"12.0","value":"NA"},{"groupId":"OG002","lowerLimit":"1.3","upperLimit":"10.5","value":"5.26"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG003","lowerLimit":"9.3","upperLimit":"14.5","value":"NA"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG005","lowerLimit":"32.3","upperLimit":"32.3","value":"NA"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG006","lowerLimit":"29.2","upperLimit":"29.2","value":"NA"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG007","lowerLimit":"10.0","upperLimit":"18.9","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"2"}],"units":"Participants"}],"title":"WEEK 13 DAY 1"},{"categories":[{"measurements":[{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG006","lowerLimit":"10.0","upperLimit":"10.0","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"WEEK 13 DAY 8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"14"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"15"}],"units":"Participants"}],"description":"Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.","dispersionType":"Full Range","groups":[{"description":"Participants with RRMM received belantamab mafodotin as 1.9 mg/kg dose on Day 1 of every alternate 21-day cycle (C1, C3, C5, C7, and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib (Bor) was administered as 1.3 milligrams per square meters (mg/m\\^2) subcutaneously (SC) /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone (Dex) PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG000","title":"Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 1.9 mg/kg on Day 1 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG001","title":"Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as 2.5 mg/kg dose on cycle 1 day 1 (C1D1) followed by 1.9 mg/kg step-down dose on Day 1 of every alternate 21-day cycles C3 onwards (C3, C5, C7, and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG002","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as 2.5 mg/kg dose on Day 1 of every alternate 21-day cycles (C1, C3, C5, C7, and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG003","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as two equal divided doses of a total 2.5mg/kg dose as a 1.25 mg/kg on Day 1 and 1.25 mg/kg dose on Day 8 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG004","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 2.5 mg/kg on Day 1 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG005","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as two equal divided doses of a total 3.4 mg/kg dose as a 1.7 mg/kg dose on Day 1 and 1.7 mg/kg on Day 8 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG006","title":"Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 3.4 mg/kg on Day 1 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG007","title":"Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex"}],"paramType":"MEDIAN","populationDescription":"Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.","reportingStatus":"POSTED","timeFrame":"Pre-Dose, Post-Dose 0, 2 and 24 Hour on Cycle 1 Day 1 and Cycle 1 Day 8; Pre-Dose and Post-Dose on Week 4 Day 1, Week 7 Day 1, Week 7 Day 8, Week 10 Day 1, Week 13 Day 1, Week 13 Day 8","title":"Ctrough for Belantamab Mafodotin (Total Antibody), Treatment B","type":"SECONDARY","unitOfMeasure":"ug/mL"}